London
· Delayed Price · Currency is GBP · Price in USD Abeona Therapeutics Company Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
| Country | United States |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Vishwas Seshadri |
Contact Details
Address: 6555 Carnegie Avenue Cleveland, Delaware 44103 United States | |
| Phone | 646 813 4701 |
| Website | abeonatherapeutics.com |
Stock Details
| Ticker Symbol | 0H7R |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US00289Y2063 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Brian Kevany Ph.D. | Senior Vice President, Chief Technology Officer and CSO |
| Gregory Gin | Vice President of Investor Relations and Corporate Communications |
| Alison Hardgrove | Chief People Officer |
| Jon Voss | Vice President and Head of Quality |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior Vice President, Chief Commercial Officer and Head of Business Development |
| Carl Denny | Senior Vice President of Regulatory Affairs |